CNR2 and Parkinson disease: In particular, in addition to the above described in vitro experiments, He et al. have also analyzed the effects of the selective CB2 receptor agonist AM1241 in a mouse model of PD obtained with MPTP, using CB1 receptor knockout (CB1-KO), CB2 receptor knockout (CB2-KO) and WT mice [49].